Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.

Cancer Med · 2022 · PMC9385593 · PMID 35297215

Europe PMC DOI

hedged sentence

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

borderline significantp = 0.062so close (0.05 < p ≤ 0.1)

Positive Autoantibodies at the 2nd blood draw were not significantly related to response, as defined by DCR or ORR (Table 4 ), although borderline significant when adjusted for cancer type (DCR: RD = −0.332 95% CI −0.682 to 0.017, p = 0.062).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.